In this population, tear film disruption and tear meniscus thickness were measured. The median tear meniscus thickness was 0.7mm and the tear film break-up time was 10 seconds. This was significantly lower (p<0.0001) than in tear-film evaluation groups and lower than the average tear meniscus thickness seen in normal eyes. Only a weak relationship was seen between tear film disruption and tear meniscus thickness.
The cause of dry eye is poorly understood. The condition may be more common in women and associated with aging. There may also be a genetic component. The management and diagnosis of dry eye is also challenging.
The prevalence of dry eye in the United States is 1 to 2% among the general general population and is much higher among women aged over 70 years.
Symptoms that are associated with dry eye include itchiness and irritation, tearing and swelling of the eyes, a feeling of burning in the eyes, blurry vision and pain. The signs of dry eye include blurred vision, tearing, redness, tearing, swelling, and dry mucosa and superficial punctate keratopathy. It is difficult to identify these signs through assessment alone. A complete eye examination helps to identify the most common presenting signs of dry eye. Dry eye can be treated with appropriate topical or systemic treatment, and it can be prevented with tear production stimulating agents.
The most common treatments for dry eye are hydrogel contact lenses and artificial tears. In more severe cases, more expensive and lengthy alternatives arise such as punctal plugs.
The long-term effects of dry eye (dysfunction of the eye that causes blurred vision, tearing, and corneal edema) may not be fully reversible. However, most cases resolve satisfactorily with prolonged eye lubricants or surgery.
The 5% product contains lifitegrast, a new topical treatment for dry eye that is FDA approved for such indications. Specifically, lifitegrast has ocular hypotensive properties, resulting in reduced fluid outflow in the aqueous and aqueous-vitreous systems. These properties contribute to the clinical benefits of lifitegrast therapy for dry eye diseases. The FDA approved the product for the treatment of dry eye and for the mitigation of ocular hypotensive symptoms for patients with glaucoma. The indications have the same restrictions found among other ophthalmic topical medications which are medically approved for the condition of dry eye.
Lifitegrast 5% may be used as monotherapy. Lifitegrast 5% may optionally be used in combination with other topical treatments that have shown some positive effects on dry eye. More studies are needed to find out if these combinations are more effective in dry eye resolution than treatment with only one of these modalities.
Results from a recent paper suggest lifitegrast with 5% is more effective as a treatment than a placebo for mild to moderate dry eye symptoms. This treatment regimen had acceptable safety.
There are many studies that are new in the field of dry eye; this is a growing area of research. However, there are no medications that can help dry eye. This research will help us to understand more about this debilitating disease in the future. It is just the beginning\n
Lifitegrast 5% ophthalmic solution is an effective and well-tolerated treatment for meibomian gland dysfunction, particularly in patients reporting meibomian gland symptoms despite using meibomian gland stimulating drops at baseline.